<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(16)</volume><submitter>Huang CW</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Growing evidence has demonstrated that aberrant expression of integrin α2β1 might contribute to the invasion, metastasis and drug resistance of non-small cell lung cancer (NSCLC). Thus, the integrin α2β1 targeting &lt;sup>68&lt;/sup>Ga-DOTA-A2B1 tracer was validated in NSCLC in contrast to accumulation of the clinically used &lt;sup>18&lt;/sup>F-FDG PET tracer to see if &lt;sup>68&lt;/sup>Ga-DOTA-A2B1-PET imaging can offer a valuable and critical diagnostic imaging criterion for the identification of phenotypes of aggressive lung cancer.&lt;h4>Methods&lt;/h4>To verify the prognostic value of integrin α2β1, several quantitative and functional &lt;i>in vitro&lt;/i> assays were validated in different NSCLC cell lines (CL1-0, CL1-5, A549 and selected A549&lt;sup>++&lt;/sup> cells). Positron emission tomography (P</pubmed_abstract><journal>Theranostics</journal><pagination>4013-4028</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5667422</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Use of PET Imaging for Prognostic Integrin α&lt;sub>2&lt;/sub>β&lt;sub>1&lt;/sub> Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses.</pubmed_title><pmcid>PMC5667422</pmcid><pubmed_authors>Hsu ST</pubmed_authors><pubmed_authors>Wu CP</pubmed_authors><pubmed_authors>Huang FT</pubmed_authors><pubmed_authors>Lin YH</pubmed_authors><pubmed_authors>Huang CW</pubmed_authors><pubmed_authors>Hsieh WC</pubmed_authors><pubmed_authors>Chiu H</pubmed_authors><pubmed_authors>Lin YW</pubmed_authors><pubmed_authors>Yen TC</pubmed_authors><pubmed_authors>Chung YH</pubmed_authors><pubmed_authors>Chang WC</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Use of PET Imaging for Prognostic Integrin α&lt;sub>2&lt;/sub>β&lt;sub>1&lt;/sub> Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses.</name><description>&lt;h4>Purpose&lt;/h4>Growing evidence has demonstrated that aberrant expression of integrin α2β1 might contribute to the invasion, metastasis and drug resistance of non-small cell lung cancer (NSCLC). Thus, the integrin α2β1 targeting &lt;sup>68&lt;/sup>Ga-DOTA-A2B1 tracer was validated in NSCLC in contrast to accumulation of the clinically used &lt;sup>18&lt;/sup>F-FDG PET tracer to see if &lt;sup>68&lt;/sup>Ga-DOTA-A2B1-PET imaging can offer a valuable and critical diagnostic imaging criterion for the identification of phenotypes of aggressive lung cancer.&lt;h4>Methods&lt;/h4>To verify the prognostic value of integrin α2β1, several quantitative and functional &lt;i>in vitro&lt;/i> assays were validated in different NSCLC cell lines (CL1-0, CL1-5, A549 and selected A549&lt;sup>++&lt;/sup> cells). Positron emission tomography (P</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2026-04-16T07:11:12.069Z</modification><creation>2019-03-27T03:00:41Z</creation></dates><accession>S-EPMC5667422</accession><cross_references><pubmed>29109795</pubmed><doi>10.7150/thno.19304</doi></cross_references></HashMap>